In This Article:
Global markets have experienced significant shifts, with U.S. stocks rallying to record highs following a Republican "red sweep" in the recent elections, sparking hopes for growth and tax reforms. Amid these changes, investors are increasingly seeking opportunities in smaller or newer companies often referred to as penny stocks—a term that may sound outdated but remains relevant today. These stocks can offer growth potential at lower price points, especially when they possess strong financials and solid fundamentals.
Top 10 Penny Stocks
Name | Share Price | Market Cap | Financial Health Rating |
BP Plastics Holding Bhd (KLSE:BPPLAS) | MYR1.22 | MYR351.85M | ★★★★★★ |
Rexit Berhad (KLSE:REXIT) | MYR0.785 | MYR136.84M | ★★★★★★ |
Lever Style (SEHK:1346) | HK$0.87 | HK$552.27M | ★★★★★★ |
DXN Holdings Bhd (KLSE:DXN) | MYR0.475 | MYR2.29B | ★★★★★★ |
Embark Early Education (ASX:EVO) | A$0.765 | A$144.95M | ★★★★☆☆ |
Seafco (SET:SEAFCO) | THB2.04 | THB1.67B | ★★★★★★ |
LaserBond (ASX:LBL) | A$0.6075 | A$72.68M | ★★★★★★ |
Wellcall Holdings Berhad (KLSE:WELLCAL) | MYR1.53 | MYR761.86M | ★★★★★★ |
ME Group International (LSE:MEGP) | £2.25 | £847.72M | ★★★★★★ |
Supreme (AIM:SUP) | £1.63 | £190.08M | ★★★★★★ |
Click here to see the full list of 5,755 stocks from our Penny Stocks screener.
We'll examine a selection from our screener results.
Brii Biosciences
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Brii Biosciences Limited focuses on developing therapies for infectious and central nervous system diseases in China and the United States, with a market cap of approximately HK$789.65 million.
Operations: The company's revenue is derived entirely from its biotechnology segment, amounting to CN¥38.38 million.
Market Cap: HK$789.65M
Brii Biosciences, with a market cap of approximately HK$789.65 million, operates in the biotech sector focusing on infectious and central nervous system diseases. The company is pre-revenue, generating CN¥38.38 million entirely from its biotechnology segment. Despite being unprofitable, Brii has reduced losses by 41.3% annually over the past five years and maintains a sufficient cash runway for more than three years without debt concerns. Recent events include its exclusion from the S&P Global BMI Index and reporting increased net losses for H1 2024 compared to last year, highlighting ongoing financial challenges amidst strategic developments in its pipeline.
-
Take a closer look at Brii Biosciences' potential here in our financial health report.
-
Examine Brii Biosciences' earnings growth report to understand how analysts expect it to perform.
China Health Group
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: China Health Group Limited, with a market cap of HK$344.15 million, operates as an investment holding company focused on the distribution and services of medical equipment and consumables in the People's Republic of China.